Jun 15, 2020
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
Jun 04, 2020
New Long-term Data from RINVOQ(TM) (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
Jun 03, 2020
EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Jun 01, 2020
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ(TM) (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Jun 01, 2020
Despite Increased Competition from the Recent Launch of Janssen's Stelara, Takeda's Entyvio Continues to Shine as a Leading Ulcerative Colitis Treatment
Apr 24, 2020
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
Apr 10, 2020
Lilly Begins Clinical Testing of Therapies for COVID-19
Mar 31, 2020
3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2%
Mar 16, 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Feb 05, 2020
RINVOQ(TM) (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis
Feb 03, 2020
Global Arthritis Therapeutics Market to Grow at Over 6% Annually to Reach USD 72 Billion Valuation by 2027: Transparency Market Research
Dec 06, 2019
FDA Approves Amgen's AVSOLA(TM) (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
Nov 11, 2019
TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
Nov 08, 2019
Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting
Oct 21, 2019
STELARA® (ustekinumab) Data Demonstrate Long-Term Efficacy and Safety Results in Adults with Moderately to Severely Active Ulcerative Colitis in Phase 3 Extension Trial
Oct 21, 2019
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Oct 09, 2019
AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress
Oct 07, 2019
Janssen Submits Application to U.S. FDA Seeking Approval of STELARA®(ustekinumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Aug 30, 2019
Innovent Biologics Study Results of IBI303 in Patients with Ankylosing Spondylitis was Published in "The Lancet Rheumatology"
Aug 26, 2019
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)